SCHEMBL3017410

SCHEMBL3017410

COc1cc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)cc(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.36
F2RL3 Q96RI0 4/20 0.36
F2 P00734 1/20 0.36
TP53 P04637 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
RECQL P46063 2/20 0.35
USP2 O75604 1/20 0.35
HSD17B10 Q99714 1/20 0.35
POLB P06746 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HTT P42858 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2999661 0.93 MAPT (0.40) MAPTTP53LMNARAB9ASMN1; SMN2
SCHEMBL2999478 0.93 CTSS (0.36) MAPTF2RL3F2LMNARAB9A
SCHEMBL3020224 0.92 MAPT (0.41) MAPTF2RL3F2TP53LMNA
SCHEMBL3013816 0.92 TP53 (0.38) MAPTF2RL3F2TP53LMNA
SCHEMBL3010750 0.90 CTSS (0.40) MAPTF2RL3F2TP53LMNA
SCHEMBL3006085 0.90 GAA (0.38) MAPTLMNARAB9ASMN1; SMN2RECQL
SCHEMBL3014619 0.90 CYP3A4 (0.39) MAPTF2RL3F2TP53LMNA
SCHEMBL3016369 0.88 LMNA (0.44) MAPTTP53LMNARAB9ARECQL
SCHEMBL3009031 0.88 PSEN1 (0.36) MAPTF2RL3F2TP53LMNA
SCHEMBL3017811 0.88 TSHR (0.36) MAPTRAB9ASMN1; SMN2RECQLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885F2RL3 3732/4885F2 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.